NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 08/28/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization65.4 mln
Float25.23 mln
Earnings Date11/16/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-8.74
Highly reliable
Relative Strength
32
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-99.55
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Talphera Inc. is a California-based pharmaceutical company focused on treatments used under direct medical supervision. Its leading program, Niyad, is a specialized formulation designed to prevent blood clotting during procedures that route blood outside the body. The company is also working on additional treatments targeting serious conditions such as viral infections, respiratory failure, and abnormal clotting disorders. Originally founded in 2005 as AcelRx Pharmaceuticals, it adopted its current name in early 2024.
